JAK redux: A second look at the regulation and role of JAKs in the heart

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 297, Issue 5, 2009, Pages

  Kurdi, Mazen ^a,b   Booz, George W ^b  

^a LEBANESE UNIVERSITY   (Lebanon)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiac myocyte; Cardiac remodeling; Cytokine; Janus kinase; Oxidative stress; Redox

Indexed keywords

ADAPTOR PROTEIN; JANUS KINASE 1; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; REPERFUSION INJURY SALVAGE KINASE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HEART MUSCLE CELL; HUMAN; NITRATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACID SEQUENCE; ANIMALS; CYTOKINES; ENZYME ACTIVATION; HEART DISEASES; HUMANS; JANUS KINASE 1; JANUS KINASE 2; MOLECULAR SEQUENCE DATA; MYOCARDIUM; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 70350440089     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00032.2009     Document Type: Review

References (191)

1. Abe J, Berk BC. Fyn and JAK2 mediate Ras activation by reactive oxygen species. J Biol Chem 274: 21003-21010, 1999. (Pubitemid 129519602)
2. Abe Y, Ono K, Kawamura T, Wada H, Kita T, Shimatsu A, Hasegawa K. Leptin induces elongation of cardiac myocytes and causes eccentric left ventricular dilatation with compensation. Am J Physiol Heart Circ Physiol 292: H2387-H2396, 2007. (Pubitemid 47084621)
3. Albacker TB, Carvalho G, Schricker T, Lachapelle K. Myocardial protection during elective coronary artery bypass grafting using high-dose insulin therapy. Ann Thorac Surg 84: 1920-1927, 2007.
4. 1 receptor in response to angiotensin II. Biochem Biophys Res Commun 249: 672-677, 1998.
5. Amiri F, Venema VJ, Wang X, Ju H, Venema RC, Marrero MB. Hyperglycemia enhances angiotensin II-induced janus-activated kinase/ STAT signaling in vascular smooth muscle cells. J Biol Chem 274: 32382-32386, 1999. (Pubitemid 129503840)
6. Ancey C, Menet E, Corbi P, Fredj S, Garcia M, Rücker-Martin C, Bescond J, Morel F, Wijdenes J, Lecron JC, Potreau D. Human cardiomyocyte hypertrophy induced in vitro by gp130 stimulation. Cardiovasc Res 59: 78-85, 2003. (Pubitemid 36776374)
7. 2-terminal kinase pathway in human neutrophils. J Biol Chem 277: 40687-40696, 2002.
8. Baker JE, Su J, Hsu A, Shi Y, Zhao M, Strande JL, Fu X, Xu H, Eis A, Komorowski R, Jensen ES, Tweddell JS, Rafiee P, Gross GJ. Human thrombopoietin reduces myocardial infarct size, apoptosis, and stunning following ischaemia/reperfusion in rats. Cardiovasc Res 77: 44-53, 2008. (Pubitemid 351195154)
9. Banes-Berceli AK, Ketsawatsomkron P, Ogbi S, Patel B, Pollock DM, Marrero MB. Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am J Physiol Heart Circ Physiol 293: H1291-H1299, 2007. (Pubitemid 47254232)
10. Banes-Berceli AK, Ogobi S, Tawfik A, Patel B, Shirley A, Pollock DM, Fulton D, Marrero MB. Endothelin-1 activation of JAK2 in vascular smooth muscle cells involves NAD(P)H oxidase-derived reactive oxygen species. Vascul Pharmacol 43: 310-319, 2005. (Pubitemid 41608754)
11. Beckles DL, Mascareno E, Siddiqui MA. Inhibition of Jak2 phosphorylation attenuates pressure overload cardiac hypertrophy. Vascul Pharmacol 45: 350-357, 2006. (Pubitemid 44765297)
12. Berry MF, Pirolli TJ, Jayasankar V, Morine KJ, Moise MA, Fisher O, Gardner TJ, Patterson PH, Woo YJ. Targeted overexpression of leukemia inhibitory factor to preserve myocardium in a rat model of postinfarction heart failure. J Thorac Cardiovasc Surg 128: 866-875, 2004. (Pubitemid 39575292)
13. Binbrek AS, Mittal B, Rao KN, Sobel BE. The potential of erythropoietin for conferring cardioprotection complementing reperfusion. Coron Artery Dis 18: 583-585, 2007. (Pubitemid 47556392)
14. Bingisser RM, Tilbrook PA, Holt PG, Kees UR. Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling pathway. J Immunol 160: 5729-5734, 1998.
15. Bolli R, Dawn B, Xuan YT. Role of the JAK-STAT pathway in protection against myocardial ischemia/reperfusion injury. Trends Cardiovasc Med 13: 72-79, 2003. (Pubitemid 36175531)
16. Booz GW. Left ventricular physiology in hypertension. In: Comprehensive Hypertension, edited by Lip YH, Hall JE. Philadelphia, PA: Mosby, 2007.
17. Brar BK, Stephanou A, Pennica D, Latchman DS. CT-1 mediated cardioprotection against ischaemic re-oxygenation injury is mediated by PI3 kinase, Akt and MEK1/2 pathways. Cytokine 16: 93-96, 2001. (Pubitemid 34081702)
18. Butler KL, Huffman LC, Koch SE, Hahn HS, Gwathmey JK. STAT-3 activation is necessary for ischemic preconditioning in hypertrophied myocardium. Am J Physiol Heart Circ Physiol 291: H797-H803, 2006.
19. Casey TM, Arthur PG, Bogoyevitch MA. Necrotic death without mitochondrial dysfunction-delayed death of cardiac myocytes following oxidative stress. Biochim Biophys Acta 1773: 342-351, 2007.
20. Chan CY, Chen YS, Lee HH, Huang HS, Lai YL, Chen CF, Ma MC. Erythropoietin protects post-ischemic hearts by preventing extracellular matrix degradation: role of Jak2-ERK pathway. Life Sci 81:717-723, 2007.
21. Chatti K, Farrar WL, Duhé RJ. Tyrosine phosphorylation of the Janus kinase 2 activation loop is essential for a high-activity catalytic state but dispensable for a basal catalytic state. Biochemistry 43: 4272-4283, 2004. (Pubitemid 38445648)
22. Combet C, Blanchet C, Geourjon C, Deléage G. NPS@: network protein sequence analysis. Trends Biochem Sci 25: 147-150, 2000.
23. Craig R, Wagner M, McCardle T, Craig AG, Glembotski CC. The cytoprotective effects of the glycoprotein 130 receptor-coupled cytokine, cardiotrophin-1, require activation of NF-κB. J Biol Chem 276: 37621-37629, 2001. (Pubitemid 37384189)
24. Davidson SM, Hausenloy D, Duchen MR, Yellon DM. Signalling via the reperfusion injury signalling kinase (RISK) pathway links closure of the mitochondrial permeability transition pore to cardioprotection. Int J Biochem Cell Biol 38: 414-419, 2006. (Pubitemid 41821888)
25. Dawn B, Xuan YT, Guo Y, Rezazadeh A, Stein AB, Hunt G, Wu WJ, Tan W, Bolli R. IL-6 plays an obligatory role in late preconditioning via JAK-STAT signaling and upregulation of iNOS and COX-2. Cardiovasc Res 64: 61-71, 2004. (Pubitemid 39208923)
26. de la Torre P, Diaz-Sanjuan T, Garcia-Ruiz I, Esteban E, Canga F, Munoz-Yague T, Solis-Herruzo JA. Interleukin-6 increases rat metalloproteinase- 13 gene expression through Janus kinase-2-mediated inhibition of serine/threonine phosphatase-2A. Cell Signal 17: 427-435, 2005. (Pubitemid 39643061)
27. Deindl E, Zaruba MM, Brunner S, Huber B, Mehl U, Assmann G, Hoefer IE, Mueller-Hoecker J, Franz WM. G-CSF administration after myocardial infarction in mice attenuates late ischemic cardiomyopathy by enhanced arteriogenesis. FASEB J 20: 956-958, 2006. (Pubitemid 44961988)
28. Demyanets S, Kaun C, Rychli K, Rega G, Pfaffenberger S, Afonyushkin T, Bochkov VN, Maurer G, Huber K, Wojta J. The inflammatory cytokine oncostatin M induces PAI-1 in human vascular smooth muscle cells in vitro via PI3-kinase and ERK1/2-dependent pathways. Am J Physiol Heart Circ Physiol 293: H1962-H1968, 2007. (Pubitemid 47367248)
29. Di Bona D, Cippitelli M, Fionda C, Cammà C, Licata A, Santoni A, Craxμ A. Oxidative stress inhibits IFN-α-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol 45: 271-279, 2006.
30. Downey JM, Davis AM, Cohen MV. Signaling pathways in ischemic preconditioning. Heart Fail Rev 12: 181-188, 2007.
31. Duan C, Li M, Rui L. SH2-B promotes insulin receptor substrate 1 (IRS1)- and IRS2-mediated activation of the phosphatidylinositol 3-kinase pathway in response to leptin. J Biol Chem 279: 43684-43691, 2004. (Pubitemid 39390672)
32. Dubois MJ, Bergeron S, Kim HJ, Dombrowski L, Perreault M, Fournes B, Faure R, Olivier M, Beauchemin N, Shulman GI, Siminovitch KA, Kim JK, Marette A. The SHP-1 protein tyrosine phosphatase negatively modulates glucose homeostasis. Nat Med 12: 549-556, 2006.
33. Duhé RJ, Evans GA, Erwin RA, Kirken RA, Cox GW, Farrar WL. Nitric oxide and thiol redox regulation of Janus kinase activity. Proc Natl Acad Sci USA 95: 126-131, 1998. (Pubitemid 28103918)
34. d'Uscio LV, Smith LA, Santhanam AV, Richardson D, Nath KA, Katusic ZS. Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension 49: 1142-1148, 2007.
35. El-Adawi H, Deng L, Tramontano A, Smith S, Mascareno E, Ganguly K, Castillo R, El-Sherif N. The functional role of the JAK-STAT pathway in post-infarction remodeling. Cardiovasc Res 57: 129-138, 2003. (Pubitemid 36009444)
36. Elsasser TH, Kahl S, Li CJ, Sartin JL, Garrett WM, Rodrigo J. Caveolae nitration of Janus kinase-2 at the 1007Y-1008Y site: coordinating inflammatory response and metabolic hormone readjustment within the somatotropic axis. Endocrinology 148: 3803-12813, 2007.
37. Elsasser TH, Li CJ, Caperna TJ, Kahl S, Schmidt WF. Growth hormone (GH)-associated nitration of Janus kinase-2 at the 1007Y- 1008Y epitope impedes phosphorylation at this site: mechanism for and impact of a GH, AKT, and nitric oxide synthase axis on GH signal transduction. Endocrinology 148: 3792-3802, 2007.
38. Feener EP, Rosario F, Dunn SL, Stancheva Z, Myers MG Jr. Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol Cell Biol 24: 4968-4978, 2004. (Pubitemid 38668060)
39. Feng J, Witthuhn BA, Matsuda T, Kohlhuber F, Kerr IM, Ihle JN. Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol 17: 2497-2501, 1997. (Pubitemid 27175130)
40. Ferrand A, Kowalski-Chauvel A, Bertrand C, Escrieut C, Mathieu A, Portolan G, Pradayrol L, Fourmy D, Dufresne M, Seva C. A novel mechanism for JAK2 activation by a G protein-coupled receptor, the CCK2R: implication of this signaling pathway in pancreatic tumor models. J Biol Chem 280: 10710-10715, 2005. (Pubitemid 40395932)
41. Fischer P, Hilfiker-Kleiner D. Survival pathways in hypertrophy and heart failure: the gp130-STAT axis. Basic Res Cardiol 102: 393-411, 2007. (Pubitemid 47278812)
42. Florholmen G, Thoresen GH, Rustan AC, Jensen J, Christensen G, Aas V. Leukaemia inhibitory factor stimulates glucose transport in isolated cardiomyocytes and induces insulin resistance after chronic exposure. Diabetologia 49: 724-731, 2006. (Pubitemid 43357546)
43. 2+ and PKCδ for Janus kinase 2 activation by angiotensin II: involvement of PYK2. Mol Endocrinol 16: 367-377, 2002.
44. Fuhrer DK, Yang YC. Complex formation of JAK2 with PP2A, P13K, and Yes in response to the hematopoietic cytokine interleukin-11. Biochem Biophys Res Commun 224: 289-296, 1996.
45. Fujio Y, Kunisada K, Hirota H, Yamauchi-Takihara K, Kishimoto T. Signals through gp130 upregulate bcl-x gene expression via STAT1- binding cis-element in cardiac myocytes. J Clin Invest 99: 2898-2905, 1997. (Pubitemid 27278666)
46. Funakoshi-Tago M, Pelletier S, Moritake H, Parganas E, Ihle JN. Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity. Mol Cell Biol 28: 1792 - 1801, 2008.
47. Funakoshi-Tago M, Tago K, Kasahara T, Parganas E, Ihle JN. Negative regulation of Jak2 by its auto-phosphorylation at tyrosine 913 via the Epo signaling pathway. Cell Signal 20: 1995-2001, 2008.
48. + exchange through Janus kinase 2 and calmodulin. J Biol Chem 278: 16908-16915, 2003.
49. Gatsios P, Terstegen L, Schliess F, Häussinger D, Kerr IM, Heinrich PC, Graeve L. Activation of the Janus kinase/signal transducer and activator of transcription pathway by osmotic shock. J Biol Chem 273: 22962-22968, 1998. (Pubitemid 28417472)
50. 1 and Mas receptors. Am J Physiol Heart Circ Physiol 293: H1154-H1163, 2007.
51. Godeny MD, Sayyah J, VonDerLinden D, Johns M, Ostrov DA, Caldwell-Busby J, Sayeski PP. The N-terminal SH2 domain of the tyrosine phosphatase, SHP-2, is essential for Jak2-dependent signaling via the angiotensin II type AT1 receptor. Cell Signal 19: 600-609, 2007. (Pubitemid 46107811)
52. González A, Ravassa S, Loperena I, López B, Beaumont J, Querejeta R, Larman M, Díez J. Association of depressed cardiac gp130-mediated antiapoptotic pathways with stimulated cardiomyocyte apoptosis in hypertensive patients with heart failure. J Hypertens 25: 2148-2157, 2007. (Pubitemid 47476314)
53. 2 and Jak2-independent antioxidant features of the Jak2 inhibitor AG490. Glia 55: 1313-1324, 2007.
54. Groen A, Lemeer S, van der Wijk T, Overvoorde J, Heck AJ, Ostman A, Barford D, Slijper M, den Hertog J. Differential oxidation of protein-tyrosine phosphatases. J Biol Chem 280: 10298-10304, 2005.
55. Gross ER, Gross GJ. Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs 12: 367-388, 2007.
56. Gross ER, Hsu AK, Gross GJ. The JAK/STAT pathway is essential for opioid-induced cardioprotection: JAK2 as a mediator of STAT3, Akt, and GSK-3β. Am J Physiol Heart Circ Physiol 291: H827-H834, 2006.
57. Gu Y, Zou Y, Aikawa R, Hayashi D, Kudoh S, Yamauchi T, Uozumi H, Zhu W, Kadowaki T, Yazaki Y, Komuro I. Growth hormone signalling and apoptosis in neonatal rat cardiomyocytes. Mol Cell Biochem 223: 35-46, 2001. (Pubitemid 32952089)
58. Guaiquil VH, Golde DW, Beckles DL, Mascareno EJ, Siddiqui MA. Vitamin C inhibits hypoxia-induced damage and apoptotic signaling pathways in cardiomyocytes and ischemic hearts. Free Radic Biol Med 37: 1419-1429, 2004.
59. Gwechenberger M, Moertl D, Pacher R, Huelsmann M. Oncostatin-M in myocardial ischemia/reperfusion injury may regulate tissue repair. Croat Med J 45: 149-157, 2004. (Pubitemid 38724577)
60. Haan S, Margue C, Engrand A, Rolvering C, Schmitz-Van de Leur H, Heinrich PC, Behrmann I, Haan C. Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J Immunol 180: 998-1007, 2008.
61. Haque SJ, Wu Q, Kammer W, Friedrich K, Smith JM, Kerr IM, Stark GR, Williams BR. Receptor-associated constitutive protein tyrosine phosphatase activity controls the kinase function of JAK1. Proc Natl Acad Sci USA 94: 8563-8568, 1997. (Pubitemid 27335078)
62. Harada M, Qin Y, Takano H, Minamino T, Zou Y, Toko H, Ohtsuka M, Matsuura K, Sano M, Nishi J, Iwanaga K, Akazawa H, Kunieda T, Zhu W, Hasegawa H, Kunisada K, Nagai T, Nakaya H, Yamauchi- Takihara K, Komuro I. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 11: 305-311, 2005. (Pubitemid 40460559)
63. Hasegawa H, Takano H, Iwanaga K, Ohtsuka M, Qin Y, Niitsuma Y, Ueda K, Toyoda T, Tadokoro H, Komuro I. Cardioprotective effects of granulocyte colony-stimulating factor in swine with chronic myocardial ischemia. J Am Coll Cardiol 47: 842-849, 2006. (Pubitemid 43243110)
64. Hattori R, Maulik N, Otani H, Zhu L, Cordis G, Engelman RM, Siddiqui MA, Das DK. Role of STAT3 in ischemic preconditioning. J Mol Cell Cardiol 33: 1929-1936, 2001.
65. Hausenloy DJ, Yellon DM. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 12: 217-234, 2007.
66. Higuchi T, Yamauchi-Takihara K, Matsumiya G, Fukushima N, Ichikawa H, Kuratani T, Maehata Y, Sawa Y. Granulocyte colony-stimulating factor prevents reperfusion injury after heart preservation. Ann Thorac Surg 85: 1367-1373, 2008.
67. Hiraoka E, Kawashima S, Takahashi T, Rikitake Y, Hirase T, Yokoyama M. PI 3-kinase-Akt-p70 S6 kinase in hypertrophic responses to leukemia inhibitory factor in cardiac myocytes. Kobe J Med Sci 49: 25-37, 2003. (Pubitemid 36830017)
68. Hirota H, Chen J, Betz UA, Rajewsky K, Gu Y, Ross J Jr, Müller W, Chien KR. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97: 189-198, 1999. (Pubitemid 29194270)
69. Hirota H, Yoshida K, Kishimoto T, Taga T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci USA 92: 4862-4866, 1995.
70. q-induced phosphoinositide 4,5- bisphosphate depletion. J Biol Chem 278: 40343-40351, 2003.
71. Huffman LC, Koch SE, Butler KL. Coronary effluent from a preconditioned heart activates the JAK-STAT pathway and induces cardioprotection in a donor heart. Am J Physiol Heart Circ Physiol 294: H257-H262, 2008.
72. Hwang YC, Shaw S, Kaneko M, Redd H, Marrero MB, Ramasamy R. Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury. FASEB J 19: 795-797, 2005. (Pubitemid 40617387)
73. Ieishi K, Nomura M, Kawano T, Fujimoto S, Ikefuji H, Noda Y, Nishikado A, Ito S. The effect of G-CSF in a myocardial ischemia reperfusion model rat. J Med Invest 54: 177-183, 2007. (Pubitemid 46769080)
74. Ishida-Takahashi R, Rosario F, Gong Y, Kopp K, Stancheva Z, Chen X, Feener EP, Myers MG Jr. Phosphorylation of Jak2 on Ser523 inhibits Jak2-dependent leptin receptor signaling. Mol Cell Biol 26: 4063-4073, 2006. (Pubitemid 43788010)
75. Jang EH, Park CS, Lee SK, Pie JE, Kang JH. Excessive nitric oxide attenuates leptin-mediated signal transducer and activator of transcription 3 activation. Life Sci 80: 609-617, 2007.
76. Jiao H, Berrada K, Yang W, Tabrizi M, Platanias LC, Yi T. Direct association with and dephosphorylation of Jak2 kinase by the SH2- domain-containing protein tyrosine phosphatase SHP-1. Mol Cell Biol 16: 6985-6992, 1996. (Pubitemid 26389758)
77. Kaur N, Lu B, Monroe RK, Ward SM, Halvorsen SW. Inducers of oxidative stress block ciliary neurotrophic factor activation of Jak/STAT signaling in neurons. J Neurochem 92: 1521-1530, 2005. (Pubitemid 40389220)
78. Kim KH, Oudit GY, Backx PH. Erythropoietin protects against doxorubicin- induced cardiomyopathy via a phosphatidylinositol 3-kinase-dependent pathway. J Pharmacol Exp Ther 324: 160-169, 2008.
79. Kimura R, Maeda M, Arita A, Oshima Y, Obana M, Ito T, Yamamoto Y, Mohri T, Kishimoto T, Kawase I, Fujio Y, Azuma J. Identification of cardiac myocytes as the target of interleukin 11, a cardioprotective cytokine. Cytokine 38: 107-115, 2007. (Pubitemid 47077909)
80. Kins S, Kurosinski P, Nitsch RM, Gotz J. Activation of the ERK and JNK signaling pathways caused by neuron-specific inhibition of PP2A in transgenic mice. Am J Pathol 163: 833-843, 2003. (Pubitemid 37040120)
81. Kirken RA, Rui H, Howard OM, Farrar WL. Involvement of JAK-family tyrosine kinases in hematopoietin receptor signal transduction. Prog Growth Factor Res 5: 195-211, 1994. (Pubitemid 2092594)
82. Kobayashi H, Minatoguchi S, Yasuda S, Bao N, Kawamura I, Iwasa M, Yamaki T, Sumi S, Misao Y, Ushikoshi H, Nishigaki K, Takemura G, Fujiwara T, Tabata Y, Fujiwara H. Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiovasc Res 79: 611-620, 2008.
83. Kobayashi H, Miura T, Ishida H, Miki T, Tanno M, Yano T, Sato T, Hotta H, Shimamoto K. Limitation of infarct size by erythropoietin is associated with translocation of Akt to the mitochondria after reperfusion. Clin Exp Pharmacol Physiol 35: 812-819, 2008. (Pubitemid 351725241)
84. Kodama H, Fukuda K, Pan J, Sano M, Takahashi T, Kato T, Makino S, Manabe T, Murata M, Ogawa S. Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy. Am J Physiol Heart Circ Physiol 279: H1635-H1644, 2000. (Pubitemid 30951448)
85. Kovanen PE, Junttila I, Takaluoma K, Saharinen P, Valmu L, Li W, Silvennoinen O. Regulation of Jak2 tyrosine kinase by protein kinase C during macrophage differentiation of IL-3-dependent myeloid progenitor cells. Blood 95: 1626-1632, 2000. (Pubitemid 30120822)
86. Kurdi M, Booz GW. Can the protective actions of JAK-STAT in the heart be exploited therapeutically? Parsing the regulation of interleukin- 6-type cytokine signaling. J Cardiovasc Pharmacol 50: 126-141, 2007. (Pubitemid 47267738)
87. Kurdi M, Booz GW. Evidence that IL-6-type cytokine signaling in cardiomyocytes is inhibited by oxidative stress: parthenolide targets JAK1 activation by generating ROS. J Cell Physiol 212: 424-431, 2007. (Pubitemid 47025632)
88. Kurdi M, Booz GW. G-CSF-based stem cell therapy for the heart- unresolved issues part B: stem cells, engraftment, transdifferentiation, and bioengineering. Congest Heart Fail 13: 347-351, 2007.
89. Kurdi M, Booz GW. G-CSF-based stem cell therapy for the heart- unresolved issues part A: paracrine actions, mobilization, and delivery. Congest Heart Fail 13: 221-227, 2007.
90. Kurzer JH, Argetsinger LS, Zhou YJ, Kouadio JL, O'Shea JJ, Carter-Su C. Tyrosine 813 is a site of JAK2 autophosphorylation critical for activation of JAK2 by SH2-B beta. Mol Cell Biol 24: 4557-4570, 2004. (Pubitemid 44109138)
91. Kurzer JH, Saharinen P, Silvennoinen O, Carter-Su C. Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state. Mol Cell Biol 26: 6381-6394, 2006. (Pubitemid 44277879)
92. Kusano K, Tsutsumi Y, Dean J, Gavin M, Ma H, Silver M, Thorne T, Zhu Y, Losordo DW, Aikawa R. Long-term stable expression of human growth hormone by rAAV promotes myocardial protection postmyocardial infarction. J Mol Cell Cardiol 42: 390-399, 2007. (Pubitemid 46135607)
93. Lamb P, Haslam J, Kessler L, Seidel HM, Stein RB, Rosen J. Rapid activation of the interferon-γ signal transduction pathway by inhibitors of tyrosine phosphatases. J Interferon Res 14: 365-373, 1994.
94. Latini R, Brines M, Fiordaliso F. Do non-hemopoietic effects of erythropoietin play a beneficial role in heart failure? Heart Fail Rev 13: 415-423, 2008.
95. + exchange in KNRK and CHO cells. Assay Drug Dev Technol 1: 281-289, 2003.
96. Li M, Li Z, Morris DL, Rui L. Identification of SH2B2β as an inhibitor for SH2B1- and SH2B2α-promoted Janus kinase-2 activation and insulin signaling. Endocrinology 148: 1615-1621, 2007. (Pubitemid 46457112)
97. Li Y, Takemura G, Okada H, Miyata S, Maruyama R, Li L, Higuchi M, Minatoguchi S, Fujiwara T, Fujiwara H. Reduction of inflammatory cytokine expression and oxidative damage by erythropoietin in chronic heart failure. Cardiovasc Res 71: 684-694, 2006. (Pubitemid 44848006)
98. Li Z, Zhou Y, Carter-Su C, Myers MG Jr, Rui L. SH2B1 enhances leptin signaling by both Janus kinase 2 Tyr813 phosphorylation-dependent and -independent mechanisms. Mol Endocrinol 21: 2270-2281, 2007. (Pubitemid 47347387)
99. Lindauer K, Loerting T, Liedl KR, Kroemer RT. Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxyterminal domains reveals a mechanism for autoregulation. Protein Eng 14: 27-37, 2001. (Pubitemid 32318935)
100. Liu HT, Zhang HF, Si R, Zhang QJ, Zhang KR, Guo WY, Wang HC, Gao F. Insulin protects isolated hearts from ischemia/reperfusion injury: cross-talk between PI3-K/Akt and JNKs. Sheng Li Xue Bao 59: 651-659, 2007.
101. Liu Q, Hofmann PA. Modulation of protein phosphatase 2a by adenosine A1 receptors in cardiomyocytes: role for p38 MAPK. Am J Physiol Heart Circ Physiol 285: H97-H103, 2003. (Pubitemid 36736419)
102. López N, Diez J, Fortuño MA. Characterization of the protective effects of cardiotrophin-1 against non-ischemic death stimuli in adult cardiomyocytes. Cytokine 30: 282-292, 2005.
103. Lu C, Schwartzbauer G, Sperling MA, Devaskar SU, Thamotharan S, Robbins PD, McTiernan CF, Liu JL, Jiang J, Frank SJ, Menon RK. Demonstration of direct effects of growth hormone on neonatal cardiomyocytes. J Biol Chem 276: 22892-22900, 2001. (Pubitemid 37410978)
104. Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278: 40057-40066, 2003. (Pubitemid 37248572)
105. Lu Y, Zhou J, Xu C, Lin H, Xiao J, Wang Z, Yang B. JAK/STAT and PI3K/AKT pathways form a mutual transactivation loop and afford resistance to oxidative stress-induced apoptosis in cardiomyocytes. Cell Physiol Biochem 21: 305-314, 2008. (Pubitemid 351591422)
106. Lukashova V, Chen Z, Duhé RJ, Rola-Pleszczynski M, Stanková J. Janus kinase 2 activation by the platelet-activating factor receptor (PAFR): roles of Tyk2 and PAFR C terminus. J Immunol 171: 3794-3800, 2003. (Pubitemid 37254585)
107. Mamoon NM, Smith JK, Chatti K, Lee S, Kundrapu K, Duhé RJ. Multiple cysteine residues are implicated in Janus kinase 2-mediated catalysis. Biochemistry 46: 14810-81481, 2007. (Pubitemid 350308872)
108. Manukyan I, Galatioto J, Mascareno E, Bhaduri S, Siddiqui MA. Cross-talk between calcineurin/NFAT and Jak/STAT signaling induces cardioprotective αB-crystallin gene expression in response to hypertrophic stimuli. J Cell Mol Med (June 16, 2009). doi:10.1111/j.1582-4934.2009.00804.x.
109. Markou T, Cullingford TE, Giraldo A, Weiss SC, Alsafi A, Fuller SJ, Clerk A, Sugden PH. Glycogen synthase kinases 3α and 3β in cardiac myocytes: regulation and consequences of their inhibition. Cell Signal 20: 206-218, 2008. (Pubitemid 350138382)
110. Marrero MB, Venema VJ, Ju H, Eaton DC, Venema RC. Regulation of angiotensin II-induced JAK2 tyrosine phosphorylation: roles of SHP-1 and SHP-2. Am J Physiol Cell Physiol 275: C1216-C1223, 1998. (Pubitemid 28536288)
111. Mascareno E, Beckles DL, Siddiqui MA. Janus kinase-2 signaling mediates apoptosis in rat cardiomyocytes. Vascul Pharmacol 43: 327-335, 2005. (Pubitemid 41608756)
112. Mascareno E, El-Shafei M, Maulik N, Sato M, Guo Y, Das DK, Siddiqui MA. JAK/STAT signaling is associated with cardiac dysfunction during ischemia and reperfusion. Circulation 104: 325-329, 2001. (Pubitemid 32666955)
113. Matsushita K, Iwanaga S, Oda T, Kimura K, Shimada M, Sano M, Umezawa A, Hata J, Ogawa S. Interleukin-6/soluble interleukin-6 receptor complex reduces infarct size via inhibiting myocardial apoptosis. Lab Invest 85: 1210-1223, 2005. (Pubitemid 41348637)
114. Maures TJ, Kurzer JH, Carter-Su C. SH2B1 (SH2-B) and JAK2: a multifunctional adaptor protein and kinase made for each other. Trends Endocrinol Metab 18: 38-45, 2007. (Pubitemid 44960015)
115. Mazière C, Conte MA, Mazière JC. Activation of JAK2 by the oxidative stress generated with oxidized low-density lipoprotein. Free Radic Biol Med 31: 1334-1340, 2001.
116. Mazurkiewicz-Munoz AM, Argetsinger LS, Kouadio JL, Stensballe A, Jensen ON, Cline JM, Carter-Su C. Phosphorylation of JAK2 at serine 523: a negative regulator of JAK2 that is stimulated by growth hormone and epidermal growth factor. Mol Cell Biol 26: 4052-4062, 2006. (Pubitemid 43788009)
117. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 168: 689-695, 2002. (Pubitemid 34049569)
118. McDoom I, Ma X, Kirabo A, Lee KY, Ostrov DA, Sayeski PP. Identification of tyrosine 972 as a novel site of Jak2 tyrosine kinase phosphorylation and its role in Jak2 activation. Biochemistry 47: 8326-8334, 2008.
119. Mellado M, Rodríguez-Frade JM, Aragay A, del Real G, Martín AM, Vila-Coro AJ, Serrano A, Mayor F Jr, Martínez-AC. The chemokine monocyte chemotactic protein 1 triggers Janus kinase 2 activation and tyrosine phosphorylation of the CCR2B receptor. J Immunol 161: 805-813, 1998. (Pubitemid 28323544)
120. Meng TC, Fukada T, Tonks NK. Reversible oxidation and inactivation of protein tyrosine phosphatases in vivo. Mol Cell 9: 387-399, 2002. (Pubitemid 34195563)
121. Miki T, Miura T, Tanno M, Nishihara M, Naitoh K, Sato T, Takahashi A, Shimamoto K. Impairment of cardioprotective PI3K-Akt signaling by post-infarct ventricular remodeling is compensated by an ERK-mediated pathway. Basic Res Cardiol 102: 163-170, 2007. (Pubitemid 46189957)
122. Miyamoto S, Murphy AN, Brown JH. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ 15: 521-529, 2008. (Pubitemid 351267303)
123. Modesti A, Bertolozzi I, Gamberi T, Marchetta M, Lumachi C, Coppo M, Moroni F, Toscano T, Lucchese G, Gensini GF, Modesti PA. Hyperglycemia activates JAK2 signaling pathway in human failing myocytes via angiotensin II-mediated oxidative stress. Diabetes 54: 394-401, 2005.
124. Monroe RK, Halvorsen SW. Cadmium blocks receptor-mediated Jak/ STAT signaling in neurons by oxidative stress. Free Radic Biol Med 41: 493-502, 2006.
125. Monroe RK, Halvorsen SW. Mercury abolishes neurotrophic factor-stimulated Jak-STAT signaling in nerve cells by oxidative stress. Toxicol Sci 94: 129-138, 2006.
126. Morisco C, Marrone C, Trimarco V, Crispo S, Monti MG, Sadoshima J, Trimarco B. Insulin resistance affects the cytoprotective effect of insulin in cardiomyocytes through an impairment of MAPK phosphatase-1 expression. Cardiovasc Res 76: 453-464, 2007. (Pubitemid 350007455)
127. Mudalagiri NR, Mocanu MM, Di Salvo C, Kolvekar S, Hayward M, Yap J, Keogh B, Yellon DM. Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation. Br J Pharmacol 153: 50-56, 2008.
128. Nakaoka Y, Nishida K, Fujio Y, Izumi M, Terai K, Oshima Y, Sugiyama S, Matsuda S, Koyasu S, Yamauchi-Takihara K, Hirano T, Kawase I, Hirota H. Activation of gp130 transduces hypertrophic signal through interaction of scaffolding/docking protein Gab1 with tyrosine phosphatase SHP2 in cardiomyocytes. Circ Res 93: 221-229, 2003. (Pubitemid 36993233)
129. Negoro S, Oh H, Tone E, Kunisada K, Fujio Y, Walsh K, Kishimoto T, Yamauchi-Takihara K. Glycoprotein 130 regulates cardiac myocyte survival in doxorubicin-induced apoptosis through phosphatidylinositol 3-kinase/Akt phosphorylation and Bcl-xL/caspase-3 interaction. Circulation 103: 555-561, 2001. (Pubitemid 32116241)
130. Negoro S, Kunisada K, Fujio Y, Funamoto M, Darville MI, Eizirik DL, Osugi T, Izumi M, Oshima Y, Nakaoka Y, Hirota H, Kishimoto T, Yamauchi-Takihara K. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxygenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 104: 979-981, 2001. (Pubitemid 32803871)
131. Negoro S, Kunisada K, Tone E, Funamoto M, Oh H, Kishimoto T,
132. Nishihara M, Miura T, Miki T, Tanno M, Yano T, Naitoh K, Ohori K, Hotta H, Terashima Y, Shimamoto K. Modulation of the mitochondrial permeability transition pore complex in GSK-3β-mediated myocardial protection. J Mol Cell Cardiol 43: 564-570, 2007. (Pubitemid 47615050)
133. O'Brien KB, O'Shea JJ, Carter-Su C. SH2-B family members differentially regulate JAK family tyrosine kinases. J Biol Chem 277: 8673-8681, 2002. (Pubitemid 34968334)
134. Oh H, Fujio Y, Kunisada K, Hirota H, Matsui H, Kishimoto T, Yamauchi-Takihara K. Activation of phosphatidylinositol 3-kinase through glycoprotein 130 induces protein kinase B and p70 S6 kinase phosphorylation in cardiac myocytes. J Biol Chem 273: 9703-9710, 1998. (Pubitemid 28183061)
135. Ohori K, Miura T, Tanno M, Miki T, Sato T, Ishikawa S, Horio Y, Shimamoto K. Ser9 phosphorylation of mitochondrial GSK-3beta is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidant-induced apoptosis. Am J Physiol Heart Circ Physiol 295: H2079-H2086, 2008.
136. Osherov N, Gazit A, Gilon C, Levitzki A. Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins. J Biol Chem 268: 11134-11142, 1993. (Pubitemid 23162303)
137. Parsa CJ, Kim J, Riel RU, Pascal LS, Thompson RB, Petrofski JA, Matsumoto A, Stamler JS, Koch WJ. Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J Biol Chem 279: 20655-20662, 2004. (Pubitemid 38656460)
138. Paxton WG, Heerdt L, Berk BC, Delafontaine P, Bernstein KE. Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 375: 247-250, 1995.
139. Piuhola J, Kerkelä R, Keenan JI, Hampton MB, Richards AM, Pemberton CJ. Direct cardiac actions of erythropoietin (EPO): effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury. Clin Sci (Lond) 114: 293-304, 2008. (Pubitemid 351294005)
140. Podewski EK, Hilfiker-Kleiner D, Hilfiker A, Morawietz H, Lichtenberg A, Wollert KC, Drexler H. Alterations in Janus kinase (JAK)- signal transducers and activators of transcription (STAT) signaling in patients with end-stage dilated cardiomyopathy. Circulation 107: 798-802, 2003. (Pubitemid 36241034)
141. Ren D, Zhou Y, Morris D, Li M, Li Z, Rui L. Neuronal SH2B1 is essential for controlling energy and glucose homeostasis. J Clin Invest 117: 397-406, 2007. (Pubitemid 46203968)
142. Ricci C, Pastukh V, Mozaffari M, Schaffer SW. Insulin withdrawal induces apoptosis via a free radical-mediated mechanism. Can J Physiol Pharmacol 85: 455-464, 2007. (Pubitemid 47262251)
143. Rocher G, Letourneux C, Lenormand P, Porteu F. Inhibition of B56-containing PP2As by the early response gene IEX-1 leads to control of Akt activity. J Biol Chem 282: 5468-5477, 2007. (Pubitemid 47093774)
144. Rodig SJ, Meraz MA, White JM, Lampe PA, Riley JK, Arthur CD, King KL, Sheehan KC, Yin L, Pennica D, Johnson EM Jr, Schreiber RD. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell 93: 373-383, 1998. (Pubitemid 28232082)
145. Rojas FA, Carvalho CR, Paez-Espinosa V, Saad MJ. Regulation of cardiac Jak-2 in animal models of insulin resistance. IUBMB Life 49: 501-509, 2000. (Pubitemid 30744895)
146. Ruixing Y, Jinzhen W, Dezhai Y, Jiaquan L. Cardioprotective role of cardiotrophin-1 gene transfer in a murine model of myocardial infarction. Growth Factors 25: 286-294, 2007.
147. Saad MJ, Carvalho CR, Thirone AC, Velloso LA. Insulin induces tyrosine phosphorylation of JAK2 in insulin-sensitive tissues of the intact rat. J Biol Chem 271: 22100-22104, 1996.
148. Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem 277: 47954-47963, 2002. (Pubitemid 36159324)
149. Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol Biol Cell 14: 1448-1459, 2003. (Pubitemid 36547413)
150. Sandberg EM, Sayeski PP. Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells. J Biol Chem 279: 34547-34552, 2004.
151. 2+ mobilization and heterotrimeric G protein activation in mediating tyrosine phosphorylation signaling patterns in vascular smooth muscle cells. Mol Cell Biochem 212: 91-98, 2000.
152. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/ STAT signaling and cytokine induction. Circ Res 87: 1195-1201, 2000.
153. Shanley TP, Vasi N, Denenberg A, Wong HR. The serine/threonine phosphatase, PP2A: endogenous regulator of inflammatory cell signaling. J Immunol 166: 966-972, 2001. (Pubitemid 32060252)
154. Shaw S, Wang X, Redd H, Alexander GD, Isales CM, Marrero MB. High glucose augments the angiotensin II-induced activation of JAK2 in vascular smooth muscle cells via the polyol pathway. J Biol Chem 278: 30634-30641, 2003. (Pubitemid 36994568)
155. Sheng Z, Knowlton K, Chen J, Hoshijima M, Brown JH, Chien KR. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy. J Biol Chem 272: 5783-5791, 1997. (Pubitemid 27102409)
156. Simon AR, Rai U, Fanburg BL, Cochran BH. Activation of the JAK-STAT pathway by reactive oxygen species. Am J Physiol Cell Physiol 275: C1640-C1652, 1998. (Pubitemid 128734296)
157. Smart N, Mojet MH, Latchman DS, Marber MS, Duchen MR, Heads RJ. IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes. Cardiovasc Res 69: 164-177, 2006. (Pubitemid 41814820)
158. Smith RM, Suleman N, Lacerda L, Opie LH, Akira S, Chien KR, Sack MN. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res 63: 611-616, 2004. (Pubitemid 39078674)
159. Stein AB, Tang XL, Guo Y, Xuan YT, Dawn B, Bolli R. Delayed adaptation of the heart to stress: late preconditioning. Stroke 35, Suppl 1: 2676-2679, 2004. (Pubitemid 39458366)
160. Takahama H, Minamino T, Hirata A, Ogai A, Asanuma H, Fujita M, Wakeno M, Tsukamoto O, Okada K, Komamura K, Takashima S, Shinozaki Y, Mori H, Mochizuki N, Kitakaze M. Granulocyte colony-stimulating factor mediates cardioprotection against ischemia/reperfusion injury via phosphatidylinositol-3-kinase/Akt pathway in canine hearts. Cardiovasc Drugs Ther 20: 159-165, 2006. (Pubitemid 44099813)
161. Takahashi-Tezuka M, Yoshida Y, Fukada T, Ohtani T, Yamanaka Y, Nishida K, Nakajima K, Hibi M, Hirano T. Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol Cell Biol 18: 4109-4117, 1998. (Pubitemid 28287934)
162. Takano H, Ueda K, Hasegawa H, Komuro I. G-CSF therapy for acute myocardial infarction. Trends Pharmacol Sci 28: 512-517, 2007. (Pubitemid 47488506)
163. Takeishi Y, Huang Q, Wang T, Glassman M, Yoshizumi M, Baines CP, Lee JD, Kawakatsu H, Che W, Lerner-Marmarosh N, Zhang C, Yan C, Ohta S, Walsh RA, Berk BC, Abe J. Src family kinase and adenosine differentially regulate multiple MAP kinases in ischemic myocardium: modulation of MAP kinases activation by ischemic preconditioning. J Mol Cell Cardiol 33: 1989-2005, 2001.
164. Thirone AC, JeBailey L, Bilan PJ, Klip A. Opposite effect of JAK2 on insulin-dependent activation of mitogen-activated protein kinases and Akt in muscle cells: possible target to ameliorate insulin resistance. Diabetes 55: 942-951, 2006. (Pubitemid 44100168)
165. Tissier R, Berdeaux A, Ghaleh B, Couvreur N, Krieg T, Cohen MV, Downey JM. Making the heart resistant to infarction: how can we further decrease infarct size? Front Biosci 13: 284-301, 2008. (Pubitemid 351594778)
166. Tonks NK. Redox redux: revisiting PTPs and the control of cell signaling. Cell 121: 667-670, 2005.
167. Ueda K, Takano H, Hasegawa H, Niitsuma Y, Qin Y, Ohtsuka M, Komuro I. Granulocyte colony stimulating factor directly inhibits myocardial ischemia-reperfusion injury through Akt-endothelial NO synthase pathway. Arterioscler Thromb Vasc Biol 26: e108-e113, 2006. (Pubitemid 44305355)
168. Uozumi H, Hiroi Y, Zou Y, Takimoto E, Toko H, Niu P, Shimoyama M, Yazaki Y, Nagai R, Komuro I. gp130 plays a critical role in pressure overload-induced cardiac hypertrophy. J Biol Chem 276: 23115-23119, 2001. (Pubitemid 37411007)
169. van Montfort RL, Congreve M, Tisi D, Carr R, Jhoti H. Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B. Nature 423: 773-777, 2003. (Pubitemid 36735702)
170. Velloso LA, Carvalho CR, Rojas FA, Folli F, Saad MJ. Insulin signalling in heart involves insulin receptor substrates-1 and -2, activation of phosphatidylinositol 3-kinase and the JAK 2-growth related pathway. Cardiovasc Res 40: 96-102, 1998. (Pubitemid 28435433)
171. Vila-Coro AJ, Rodríguez-Frade JM, Martín De Ana A, Moreno- Ortíz MC, Martínez-AC, Mellado M. The chemokine SDF-1α triggers CXCR4 receptor dimerization and activates the JAK/STAT pathway. FASEB J 13: 1699-1710, 1999.
172. Wang F, Seta Y, Baumgarten G, Engel DJ, Sivasubramanian N, Mann DL. Functional significance of hemodynamic overload-induced expression of leukemia-inhibitory factor in the adult mammalian heart. Circulation 103: 1296-1302, 2001. (Pubitemid 32221355)
173. Weiss A, Schlessinger J. Switching signals on or off by receptor dimerization. Cell 94: 277-280, 1998.
174. Wu KK. Regulation of endothelial nitric oxide synthase activity and gene expression. Ann NY Acad Sci 962: 122-130, 2002. (Pubitemid 34592306)
175. Xu X, Sonntag WE. Growth hormone-induced nuclear translocation of Stat-3 decreases with age: modulation by caloric restriction. Am J Physiol Endocrinol Metab 271: E903-E909, 1996. (Pubitemid 26404714)
176. Xuan YT, Guo Y, Han H, Zhu Y, Bolli R. An essential role of the JAK-STAT pathway in ischemic preconditioning. Proc Natl Acad Sci USA 98: 9050-9055, 2001. (Pubitemid 32743867)
177. Xuan YT, Guo Y, Zhu Y, Han H, Langenbach R, Dawn B, Bolli R. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J Mol Cell Cardiol 35: 525-537, 2003. (Pubitemid 36539458)
178. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Bolli R. Endothelial nitric oxide synthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase Cε p44/42 mitogen-activated protein kinase pSer-signal transducers and activators of transcription 1/3 pathway. Circulation 116: 535-544, 2007. (Pubitemid 47450262)
179. Xuan YT, Guo Y, Zhu Y, Wang OL, Rokosh G, Messing RO, Bolli R. Role of the protein kinase C-ε-Raf-1-MEK-1/2-p44/42 MAPK signaling cascade in the activation of signal transducers and activators of transcription 1 and 3 and induction of cyclooxygenase-2 after ischemic preconditioning. Circulation 112: 1971-1978, 2005.
180. Yajima T, Yasukawa H, Jeon ES, Xiong D, Dorner A, Iwatate M, Nara M, Zhou H, Summers-Torres D, Hoshijima M, Chien KR, Yoshimura A, Knowlton KU. Innate defense mechanism against virus infection within the cardiac myocyte requiring gp130-STAT3 signaling. Circulation 114: 2364-2373, 2006. (Pubitemid 44847453)
181. Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol 5: 253, 2004.
182. Yamaura G, Turoczi T, Yamamoto F, Siddqui MA, Maulik N, Das DK. STAT signaling in ischemic heart: a role of STAT5A in ischemic preconditioning. Am J Physiol Heart Circ Physiol 285: H476-H482, 2003. (Pubitemid 36885876)
183. Yasukawa H, Hoshijima M, Gu Y, Nakamura T, Pradervand S, Hanada T, Hanakawa Y, Yoshimura A, Ross J Jr, Chien KR. Suppressor of cytokine signaling-3 is a biomechanical stress-inducible gene that suppresses gp130-mediated cardiac myocyte hypertrophy and survival pathways. J Clin Invest 108: 1459-1467, 2001. (Pubitemid 33091983)
184. Yin H, Chao J, Bader M, Chao L. Differential role of kinin B1 and B2 receptors in ischemia-induced apoptosis and ventricular remodeling. Peptides 28: 1383-1389, 2007. (Pubitemid 47088743)
185. Yokoyama N, Reich NC, Miller WT. Determinants for the interaction between Janus kinase 2 and protein phosphatase 2A. Arch Biochem Biophys 417: 87-95, 2003. (Pubitemid 36960053)
186. Yokoyama N, Reich NC, Miller WT. Involvement of protein phosphatase 2A in the interleukin-3-stimulated Jak2-Stat5 signaling pathway. J Interferon Cytokine Res 21: 369-378, 2001. (Pubitemid 32692458)
187. Yu QJ, Si R, Zhou N, Zhang HF, Guo WY, Wang HC, Gao F. Insulin inhibits β-adrenergic action in ischemic/reperfused heart: a novel mechanism of insulin in cardioprotection. Apoptosis 13: 305-317, 2008.
188. Zhang XF, Wang JF, Matczak E, Proper JA, Groopman JE. Janus kinase 2 is involved in stromal cell-derived factor-1α-induced tyrosine phosphorylation of focal adhesion proteins and migration of hematopoietic progenitor cells. Blood 97: 3342-3348, 2001.
189. Zhao J, Moch H. Absence of JH2 domain mutation of the tyrosine kinase JAK2 in renal cell carcinomas. Acta Oncol 47: 474-476, 2008.
190. Zhu QS, Robinson LJ, Roginskaya V, Corey SJ. G-CSF-induced tyrosine phosphorylation of Gab2 is Lyn kinase dependent and associated with enhanced Akt and differentiative, not proliferative, responses. Blood 103: 3305-3312, 2004. (Pubitemid 38525657)
191. Zuluaga S, Alvarez-Barrientos A, Gutierrez-Uzquiza A, Benito M, Nebreda AR, Porras A. Negative regulation of Akt activity by p38alpha MAP kinase in cardiomyocytes involves membrane localization of PP2A through interaction with caveolin-1. Cell Signal 19: 62-74, 2007. (Pubitemid 44880243)